CCEL CRYO CELL INTERNATIONAL INC
Services-Misc Health & Allied Services, NEC · NYSE · SEC CIK 862692 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.0%
TTM net income YoY-310.8%
TTM EPS YoY-380.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—
Margins
Gross margin78.5%
Operating margin0.6%
Net margin-6.2%
FCF margin14.9%
EBITDA margin3.4%
Returns
ROE—
ROA-3.1%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets126.3%
Debt / equity—
Current ratio0.86x
Interest coverage0.10x
Cash quality & payout
Operating cash flow / net income-2.53x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-08-31 | 2026Q22026-05-31 | 2026Q12026-02-28 | 2025Q4*2025-11-30 | 2025Q32025-08-31 | 2025Q22025-05-31 | 2025Q12025-02-28 | 2024Q4*2024-11-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $7.82M | $7.78M | $7.68M | $7.84M | $7.83M | $7.93M | $7.97M | $8.02M |
| Cost of revenue | $1.61M | $1.68M | $1.66M | $1.73M | $1.80M | $1.86M | $1.98M | $1.64M |
| Gross profit | $6.21M | $6.10M | $6.03M | $6.11M | $6.02M | $6.07M | $5.98M | $6.39M |
| R&D expense | $53,624 | $99,781 | $65,761 | $84,784 | $61,625 | $131,711 | $98,143 | $304,629 |
| SG&A expense | $3.78M | $4.62M | $5.01M | $5.45M | $3.88M | $4.26M | $4.64M | $6.01M |
| Operating income | $2.19M | $1.20M | $765,134 | -$3.97M | $1.90M | $1.49M | $1.06M | -$122,347 |
| Interest expense | $438,305 | $441,917 | $462,709 | $481,949 | $538,219 | $551,126 | $494,962 | $745,488 |
| Pretax income | $1.83M | $827,781 | $70,309 | -$4.63M | $1.19M | $575,103 | $533,718 | -$842,434 |
| Income tax | $554,958 | $273,195 | $23,201 | -$814,537 | $436,588 | $219,318 | $250,863 | $1.02M |
| Net income | $1.27M | $554,586 | $47,108 | -$3.82M | $749,408 | $355,785 | $282,855 | -$1.86M |
| EBITDA | $2.38M | $1.38M | $1.01M | -$3.72M | $2.09M | $1.68M | $1.30M | $126,650 |
| EPS (basic) | 0.16 | 0.07 | 0.01 | — | 0.09 | 0.04 | 0.03 | — |
| EPS (diluted) | 0.16 | 0.07 | 0.01 | — | 0.09 | 0.04 | 0.03 | — |
| Dividends declared per share | — | — | — | — | — | — | 0.25 | — |
| Weighted avg. shares (diluted) | 8.07M | 8.06M | 8.06M | — | 8.07M | 8.13M | 8.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.43M | $507,302 | $249,672 | $319,031 | $265,207 | $137,491 | $223,122 | $560,960 |
| Short-term investments | $2.80M | $2.65M | $2.65M | $2.98M | $2.96M | $4.29M | $3.26M | $2.94M |
| Receivables | $6.83M | $6.91M | $6.82M | $6.85M | $6.83M | $6.93M | $7.21M | $7.31M |
| Inventory | $533,557 | $310,170 | $356,991 | $408,794 | $655,254 | $676,764 | $730,467 | $657,703 |
| Current assets | $13.17M | $11.30M | $11.08M | $11.76M | $11.67M | $13.05M | $12.51M | $12.55M |
| PP&E, net | $20.54M | $20.67M | $20.87M | $21.03M | $21.20M | $21.39M | $21.73M | $21.89M |
| Goodwill | $1.94M | $1.94M | $1.94M | $1.94M | $1.94M | $1.94M | $1.94M | $1.94M |
| Intangibles | $829,611 | $840,765 | $851,920 | $863,074 | $874,229 | $887,321 | $904,287 | $921,254 |
| Total assets | $62.30M | $60.71M | $60.88M | $61.73M | $63.17M | $64.44M | $64.38M | $64.68M |
| Current liabilities | $15.33M | $15.93M | $17.76M | $19.79M | $18.45M | $21.75M | $21.72M | $21.60M |
| Long-term debt | $8.24M | $8.28M | $8.32M | $8.35M | $8.39M | $8.42M | $8.45M | $8.48M |
| Total debt | $8.24M | $8.28M | $8.32M | $8.35M | $8.39M | $8.42M | $8.45M | $8.48M |
| Total liabilities | $78.70M | $78.46M | $79.29M | $80.33M | $78.00M | $80.00M | $79.04M | $77.89M |
| Shareholders' equity | -$16.39M | -$17.76M | -$18.40M | -$18.61M | -$14.83M | -$15.56M | -$14.66M | -$13.22M |
| Net debt | $6.81M | $7.77M | $8.07M | $8.03M | $8.12M | $8.28M | $8.23M | $7.92M |
| Shares outstanding | 8.06M | 8.06M | 8.06M | 8.06M | 8.06M | 8.06M | 8.08M | 8.08M |
| Cash flow statement | ||||||||
| Operating cash flow | $1.14M | $1.85M | $651,827 | $1.28M | $2.54M | $707,014 | $954,063 | $2.16M |
| Capital expenditure | $101,879 | $32,701 | $67,065 | $67,226 | $38,788 | $62,408 | $62,053 | $8,348 |
| Free cash flow | $1.04M | $1.81M | $584,762 | $1.21M | $2.50M | $644,606 | $892,010 | $2.15M |
| Investing cash flow | -$180,751 | $35,039 | $19,104 | -$289,649 | $1.10M | -$1.50M | -$287,484 | -$1.12M |
| Financing cash flow | -$42,657 | -$1.62M | -$740,290 | -$937,340 | -$3.51M | $710,155 | -$1.00M | -$677,821 |
| Depreciation & amortization | $184,479 | $184,329 | $244,212 | $243,011 | $185,693 | $190,102 | $248,010 | $248,997 |
| Stock-based compensation | $92,514 | $64,000 | $158,549 | $42,903 | $36,782 | $40,000 | $297,392 | $149,693 |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | $1.21M | $2.02M | $2.02M |
| Share buybacks | $0 | — | — | $0 | $80,883 | $88,619 | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.